Clovis Oncology announces interim results for drug treating pancreatic cancer

Clovis Oncology announces interim results for drug treating pancreatic cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More

Tuesday April 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More

Tuesday March 5, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More

Monday January 28, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Rucaparib

Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More

Tuesday October 2, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, FDA

Clovis Oncology receives European validation for Rubraca cancer drug

Clovis Oncology receives European validation for Rubraca cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More

Thursday July 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More

Monday April 9, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive... Read More

Monday March 26, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy